Abstract 1733MO
Background
Transurethral resection of bladder tumour (TURBT) has been the mainstay of bladder cancer staging for a century. The objective of the trial was to assess the feasibility and efficacy of the substitution of TURBT with MRI and biopsy in the staging of patients with suspected muscle invasive bladder cancer (MIBC). The hypothesis being tested was that image directed staging would shorten time to correct treatment for MIBC patients.
Methods
Patients with suspected bladder cancer were identified via the haematuria clinic. Those with possible muscle invasive disease (assessed on a Likert scale at flexible cystoscopy) were randomised to standard TURBT assessment (Pathway 1) or MRI based assessment (Pathway 2) with tumour biopsy. Patients with probable non-muscle invasive disease (NMIBC) all underwent TURBT. Primary outcome for Feasibility Phase: proportion of patients completing allocated pathway (target 80%). Primary outcome, Efficacy Phase: time to correct treatment, defined as TURBT for NMIBC or the first of chemotherapy, radiotherapy, surgery or decision for palliative care for MIBC (target: 30 day improvement).
Results
Between May 2018 and December 2021, 143 patients were randomised, median age 74 years, 47.9% probable NMIBC, 52.1% possible MIBC. Feasibility phase: 37/39 (95% (95% CI 83-99%)) patients with MIBC followed correct pathway. Efficacy phase: Pathway 1, median time to correct MIBC treatment 98 (95% CI 72-174) days; Pathway 2 53 (95% CI 20-89) days, hazard ratio (HR) 3.4 (95% CI 1.4-8.3). Logrank test: p-value= 0.0046. Secondary outcomes include median time to correct treatment all patients: Pathway 1 37 days, Pathway 2 31 days; HR 1.3 (95% CI 0.9-1.8).
Conclusions
An MRI directed pathway led to substantial shortening of time to correct treatment for MIBC patients with no detrimental effect of time to treatment for NMIBC patients. Consideration should be given to incorporation of MRI into the standard pathway for all patients with suspected invasive bladder cancer.
Clinical trial identification
ISRCTN 35296862.
Editorial acknowledgement
Legal entity responsible for the study
University of Birmingham.
Funding
NHS Health Technology Agency.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Presenter: Camillo Guglielmo Porta
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
Presenter: Marc-Oliver Grimm
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1449MO and 1450MO
Presenter: Kate Young
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
Presenter: Sebastian Schmid
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials
Presenter: Tim Smith
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA75, 1733MO and 1734MO
Presenter: Joaquim Bellmunt
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study
Presenter: Jad Chahoud
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
512MO - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database
Presenter: Silke Gillessen
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
513MO - Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders
Presenter: Anna Jansson
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1310MO, 512MO and 513MO
Presenter: Aly-Khan Lalani
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast